PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary ERYTECH to Present at Cowen and Company 40th Annual Health Care Conference
LYON, France and CAMBRIDGE, Mass. , Feb. 26, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Gil Beyen ,
View HTML
Toggle Summary ERYTECH Enters Into Strategic Supply Partnership with the German Red Cross Blood Donor Service
Second European source of donor red blood cells secured in preparation for expanded production of red blood cell-based therapeutics LYON, France and CAMBRIDGE, Mass. , Feb. 20, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company
View HTML
Toggle Summary Monthly information related to total number of voting rights and shares composing the share capital – January 31, 2020
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France , Feb. 04, 2020 (GLOBE NEWSWIRE) -- Listing markets: Euronext Paris from Euronext (Market segment C -  ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol :
View HTML
Toggle Summary ERYTECH Announces a Poster Presentation for TRYbeCA1 at the ASCO 2020
Greater than 50% enrollment achieved in ongoing Phase 3 trial of eryaspase in pancreatic cancer Trial in Progress Poster selected for inclusion in Poster Walk LYON, France and CAMBRIDGE, Mass. , Jan. 24, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP), a clinical-stage
View HTML
Toggle Summary Monthly information related to total number of voting rights and shares composing the share capital – December 31, 2019
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France , Jan. 10, 2020 (GLOBE NEWSWIRE) -- Listing markets: Euronext Paris from Euronext (Market segment C -  ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol :
View HTML
Toggle Summary Monthly information related to total number of voting rights and shares composing the share capital – November 30, 2019
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France , Dec. 02, 2019 (GLOBE NEWSWIRE) -- Listing markets: Euronext Paris from Euronext (Market segment C -  ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol :
View HTML
Toggle Summary ERYTECH Announces Publication of its Phase 2b Trial of Eryaspase in Metastatic Pancreatic Cancer in the European Journal of Cancer
First asparaginase-based therapy to demonstrate clinical efficacy and safety in solid tumors LYON, France and CAMBRIDGE, Mass. , Nov. 25, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma  (Nasdaq and Euronext : ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by
View HTML
Toggle Summary ERYTECH to Present at Jefferies 2019 Healthcare Conference in London
LYON, France and Cambridge, Mass. , Nov. 14, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext : ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Gil Beyen , Chief
View HTML
Toggle Summary ERYTECH Provides Business Update and Reports Financial Results for the Third Quarter of 2019
Conference call and webcast on Friday, November 8 at 2:30 pm CET/8:30 am ET TRYbeCA1, Phase 3 trial of eryaspase in second line pancreatic cancer: positive safety review by independent data monitoring committee opened for patient enrollment in the United States first U.S.
View HTML
Toggle Summary ERYTECH to Host Third Quarter 2019 Conference Call and Business Update on November 8, 2019
LYON, France , Nov. 05, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host a Third Quarter
View HTML
Top